Compounds > erianin
Page last updated: 2024-09-27

erianin

Description

Erianin: from Dendrobium chrysotoxum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Dendrobium chrysotoxumspecies[no description available]OrchidaceaeA plant family of the order Asparagales. All members of the orchid family have the same bilaterally symmetrical flower structure, with three sepals, but the flowers vary greatly in color and shape.[MeSH]

Cross-References

ID SourceID
PubMed CID356759
CHEMBL ID10557
SCHEMBL ID1535646
MeSH IDM0454373

Synonyms (32)

Synonym
b817373-k388, same as
nsc-613744
nsc613744
b817373-k346
phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]-
2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol
CHEMBL10557 ,
2-methoxy-5-(3,4,5-trimethoxyphenethyl)phenol
bdbm50005478
2-methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-phenol
S9137 ,
FT-0686606
95041-90-0
erianin
UXDFUVFNIAJEGM-UHFFFAOYSA-N
SCHEMBL1535646
dendrobium chrysotoxum
Q-100898
AC-24234
DTXSID40326751
AKOS025401669
7ba ,
3'-hydroxy-3,4,4',5-tetramethoxybibenzyl
BCP07974
EX-A7098
HY-N0517
CS-0009056
mfcd06795132
CCG-267683
A851725
5-(3,4,5-trimethoxyphenethyl)-2-methoxyphenol
AS-78334

Research Excerpts

Overview

ExcerptReference
"Erianin is a natural small molecule dibenzyl compound extracted from Dendrobium officinale or Dendrobium chrysotoxum. "( Guo, Y; Hong, J; Huang, X; Jian, T; Jiang, L; Wang, S; Xie, Z; Yang, F, 2022)
"Erianin (Eri) is an ideal drug candidate for inhibiting proliferation and inducing apoptosis in the treatment of psoriasis."( Chen, W; Liu, Y; Wei, K; Yu, H; Zheng, F, 2022)
"Erianin is an active dibenzyl compound isolated from Dendrobium officinale and Dendrobium chrysotoxum and there are very few studies on molecular mechanisms and drug targets of erianin. "( Kocoglu, SS; Seçme, M; Sunay, FB, 2023)
"Erianin is a natural product extracted from Dendrobium, which possesses multiple pharmacological activities, including antioxidative and antitumor activity."( Chen, Q; Hu, Y; Song, Z; Yang, L; Zhou, G, 2020)
"Erianin is a representative index component for the quality control of the D."( Jin, CH; Jin, HL; Jin, X; Li, MY; Ma, J; Piao, LX; Ri, M; Wang, JY; Xing, Y; Xu, GH; Yang, A; Zhang, ZH; Zuo, HX, 2021)
"Erianin is a small chemical compound extracted from Dendrobium chrysotoxum and has excellent antineoplastic effects against a variety of cancers. "( Hu, X; Huang, J; Huang, L; Liang, Y; Liu, Z; Nie, H; Sun, L; Wu, F, 2021)
"Erianin is a natural product isolated from Dendrobium chrysotoxum Lindl."( Cao, Y; Liu, J; Su, C; Zhang, P, 2017)

Effects

ExcerptReference
"Erianin has been reported to inhibit tumor activity by suppressing the expression of integrins. "( Li, X; Liu, X; Ma, J; Shen, H; Xing, Y; Zeng, L, 2022)
"ERIANIN has broad-spectrum antitumor effects, and its tumor-suppressive effects have been confirmed in the study of various diseases, such as precancerous lesions of the stomach, gastric cancer, liver cancer, lung cancer, prostate cancer, bladder cancer, breast cancer, cervical cancer, osteosarcoma, colorectal cancer, leukaemia, nasopharyngeal cancer and melanoma through the multiple signaling pathways."( Gao, M; Hao, J; Liu, R; Mei, H; Qiu, M; Song, T; Wang, H; Yang, Z; Zhao, K; Zou, D, 2023)

Actions

ExcerptReference
"Erianin could cause cell cycle arrest at the G2/M phase, and the expressions of p21 and p27 were up-regulated, while the expressions of CDK1 and Cyclin B1 were down-regulated."( Cai, Z; Fang, R; Shao, J; Xu, Y, 2021)
"Erianin can inhibit the proliferation of TNBC cells and induce cell cycle arrest and apoptosis, which may ascribe to the abolish the activation of the PI3K/Akt pathway."( Cai, Z; Fang, R; Shao, J; Xu, Y, 2021)

Treatment

ExcerptReference
"Treatment with erianin induced G2/M-phase arrest, apoptosis, and autophagy in OS cells."( Cai, Z; Hua, Y; Li, S; Sun, W; Wang, H; Wang, Z; Xu, J; Yin, F; Zhang, T; Zhou, Z; Zuo, D, 2016)

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-2B chainBos taurus (cattle)IC50 (µMol)1.59000.25001.88388.7000AID214001; AID214002; AID214014; AID214033
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)1.91000.25001.87798.7000AID214001; AID214002; AID214033
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)1.91000.25001.86568.7000AID214001; AID214002; AID214033
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
microtubule-based processTubulin beta-2B chainBos taurus (cattle)
nervous system developmentTubulin beta-2B chainBos taurus (cattle)
positive regulation of axon guidanceTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
GTPase activityTubulin beta-2B chainBos taurus (cattle)
metal ion bindingTubulin beta-2B chainBos taurus (cattle)
protein heterodimerization activityTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
microtubule cytoskeletonTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID1824704Induction of apoptosis in human HepG2 cells assessed as cell shrinkage at 100 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824763Reversal of H2O2-induced cell death in human HCCLM3 cells at 10 nM pretreated for 24 hrs followed by H2O2 addition and further incubated for 24 hrs in presence of OAA by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824745Inhibition of mesenchymal transition in human SK-HEP1 cells overexpressing PC assessed as effect on N-cadherin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824734Induction of apoptosis in human HCCLM3 cells assessed as decrease in cell viability at 20 to 40 nM incubated for 48 hrs in presence of 2 mM OAA MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214001Inhibition of glutamate-dependent tubulin polymerization at 30 degrees C(0.25 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824756Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of acetyl-CoA at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824760Inhibition of mitochondrial oxidative stress in PC knockout human HCCLM3 cells assessed as reduction in NADH/NAD ratio at 10 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID103262Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824695Effect on cell cycle arrest in human HepG2 cells assessed as increase in accumulation of cells in G2/M phase at 20 to 80 nM incubated for 24 hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824717Induction of apoptosis in human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed as increase in total apoptotic cells in tumor at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by TUNEL staining based2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824727Binding affinity to recombinant pyruvate carboxylase (unknown origin) assessed as thermal stability at upto 1000 nM by cellular thermal transfer assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824731Inhibition of pyruvate carboxylase in human HCCLM3 cell lysate measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824755Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of serine at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824715Antitumor activity against human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed wet tumor weight at 25 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation (Rvb= 1.835 +/- 0.15 g)2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824692Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824703Inhibition of epithelial-mesenchymal transition in human HCCLM3 cells assessed as decrease in fibronectin expression level at 0.05 to 1 nM incubated for 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214163Inhibition of colchicine binding to tubulin isolated from bovine brain tissue1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID214159Concentration to inhibit 50% of tubulin polymerization from bovine brain1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Antineoplastic agents. 379. Synthesis of phenstatin phosphate.
AID1824699Antimigratory activity in human HCCLM3 cells assessed as inhibition of scratch closure at 0.05 to 1 nM measured after 24 hrs by wound healing assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824728Inhibition of pyruvate carboxylase in human HepG2 cells measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824761Inhibition of mitochondrial oxidative stress in PC knockout human HCCLM3 cells assessed as reduction in GSH/GSSH ratio at 10 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID84127Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824748Activation of AMPK pathway in human HCCLM3 cells assessed as increase in AMPK phosphorylation level at 5 nM measured after 1 hr by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824732Inhibition of pyruvate carboxylase in human HepG2 cells measured at 10 nM upto 24 hrs2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824697Effect on cell cycle arrest in human HepG2 cells assessed as increase accumulation of cells in G2/M phase at 20 nM measured upto 24 hrs hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824705Induction of apoptosis in human HepG2 cells assessed as cell rounding at 100 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824708Induction of apoptosis in human HepG2 cells assessed as increase cleaved PARP level measured after 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824691Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824716Induction of apoptosis in human HepG2 cells xenografted in NCR-nu/nu mouse assessed as increase in total apoptotic cells in tumor at 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by TUNEL staining based confoc2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID420699Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID1824702Inhibition of epithelial-mesenchymal transition in human HCCLM3 cells assessed as decrease in N-cadherin expression at 0.05 to 1 nM incubated for 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824712Antitumor activity against human HepG2 cells xenografted in NCR-nu/nu mouse assessed reduction in tumor growth at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214184Percentage inhibition of colchicine binding to tubulin by compound was evaluated1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Antineoplastic agents. 379. Synthesis of phenstatin phosphate.
AID1824706Induction of apoptosis in human HepG2 cells assessed as nuclear condensation at 100 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824689Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824701Inhibition of epithelial-mesenchymal transition in human HCCLM3 cells assessed as upregulation of E-cadherin expression at 0.05 to 1 nM incubated for 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824766Induction of glycolysis in PC knockout human HCCLM3 cells assessed as intracellular lactate concentration at 10 nM CheKine lactate assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824747Inhibition of mesenchymal transition in human SK-HEP1 cells overexpressing PC assessed as effect on vimentin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824698Effect on cell cycle arrest in human HepG2 cells assessed as decrease in accumulation of cells at G0/G1 phase at 20 nM measured upto 24 hrs hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824694Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured upto 400 nM measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824714Antitumor activity against human HepG2 cells xenografted in NCR-nu/nu mouse assessed wet tumor weight at 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation (Rvb= 0.92 +/- 0.13 g)2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824730Inhibition of pyruvate carboxylase in human HepG2 cell lysate measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824741Antiproliferative activity against human SK-HEP1 cells transfected with PC-flag plasmid assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824737Induction of apoptosis in human HepG2 cells transfected with PC-flag plasmid assessed as reduction in cell viability at 20 to 100 nM incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824754Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of malate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824729Inhibition of pyruvate carboxylase in human HCCLM3 cells measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID98155Compound was tested for the inhibition of L1210 leukemia cells growth in mice1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824733Inhibition of pyruvate carboxylase in human HepG2 cells measured at 0.001 to 10 nM for 24 hrs2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824767Induction of apoptosis in human HCCLM3 cells assessed as cell rounding at 20 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824693Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth at 10 to 200 nM measured up to 3 days by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824768Induction of apoptosis in human HCCLM3 cells assessed as cell shrinkage at 20 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824723Cytotoxicity against human HepG2 cells assessed as cell viability at 62.5 to 250 nM preincubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824738Induction of apoptosis in human HCCLM3 cells transfected with PC-flag plasmid assessed as reduction in cell viability at 20 to 100 nM incubated for 24 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214171Effect on the binding of radiolabeled [3H]colchicine to tubulin1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824770Induction of apoptosis in human HCCLM3 cells assessed as nuclear condensation at 20 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824744Inhibition of epithelial transition in human SK-HEP1 cells overexpressing PC assessed as effect on E-cadherin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824690Antiproliferative activity against human MHCC97 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824721Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in lung at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824740Anti-invasive activity against PC knockout human HCCLM3 cells assessed as suppression of cell invasion at 0.05 nM measured after 48 hrs by transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID9208Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID214176Inhibition of colchicine binding to tubulin was evaluated only when polymerization IC50 <=1.0 uM1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents.
AID1824711Toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as effect on body weight at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured every three days2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214014Inhibition of tubulin polymerization1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID1824718Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in heart at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824710Toxicity in NCR-nu/nu mouse bearing human HepG2 tumor assessed as effect on body weight at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured every three days2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824722Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in kidney at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824753Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of oxaloacetate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824749Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of fumarate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824759Induction of mitochondrial oxidative stress in human HCCLM3 cells overexpressing PC assessed as accumulation of ROS at 10 nM by DCFH-DA staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824769Antiinvasive activity against human HCCLM3 cells assessed as reduction in cell invasion at 0.05 to 1 nM by matrigel transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID152759Concentration required for 50% inhibition of P388 murine leukemia cell growth in MTT assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers.
AID1824709Induction of caspase-mediated apoptosis in human HepG2 cells assessed as reduction in cell viability at 100 to 400 nM incubated for 48 hrs in presence of Z-VAD-FMK by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824719Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in liver at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824765Induction of glycolysis in PC knockout human HCCLM3 cells assessed as intracellular glucose consumption at 10 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824707Induction of apoptosis in human HepG2 cells assessed as activation of caspase 3 measured after 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824752Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of ATP at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824726Competitive inhibition of recombinant pyruvate carboxylase in human HepG2 cell lysate in presence of Erianin at 20 uM for 120 mins followed by irradiation of 365 nm UV light for 15 min by Native -PAGE analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1256166Inhibition of Quorum sensing system in Chromobacterium violaceum CV026 after 24 hrs by agar-well diffusion method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1824762Cytotoxicity against human HCCLM3 cells assessed as reduction in cell viability at 5 to 20 nM incubated for 48 hrs in presence of H2O2 by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID42665Ability to inhibit Tubulin polymerization in Bovine brain1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID420701Displacement of [3H]colchicine from bovine brain tubulin at 5 uM by scintillation counting2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID82183Cytotoxicity of compound against HL-60 human leukemia cells1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID214166Inhibition of radiolabeled Colchicine binding to tubulin at 30 degrees C (0.25 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824758Induction of mitochondrial oxidative stress in human HCCLM3 cells assessed as accumulation of ROS at 10 nM by DCFH-DA staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824720Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in spleen at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214002Concentration required to inhibit the extent of glutamate-dependent tubulin polymerization by 50% at 37 degrees C(1.0 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824771Antitumor activity against human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed wet tumor weight at 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation (Rvb= 1.835 +/- 0.15 g)2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID420700Displacement of [3H]colchicine from bovine brain tubulin at 1 uM by scintillation counting2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID1824751Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of L-lactate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824700Antimigratory activity in human HCCLM3 cells assessed as inhibition of scratch closure at 0.05 to 1 nM measured after 24 hrs by transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824757Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of aspartate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824739Antimigratory activity against PC knockout human HCCLM3 cells assessed as suppression of cell migration at 0.5 nM measured after 48 hrs by wound healing assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID202827Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID106876Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824736Cytotoxicity against PC knockout human HCCLM3 cells assessed as reduction in cell viability at 20 to 100 nM measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824742Antimigratory activity in human SK-HEP1 cells overexpressing PC assessed as suppression of cell migration at 0.5 nM measured after 48 hrs by wound healing assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214167Inhibition of radiolabeled Colchicine binding to tubulin at 37 degrees C (1.0 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824746Inhibition of mesenchymal transition in human SK-HEP1 cells overexpressing PC assessed as effect on fibronectin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824713Antitumor activity against human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed reduction in tumor growth at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214033Inhibition of bovine tubulin polymerization1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents.
AID1824750Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of succinate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824764Effect on ATP production in PC knockout human HCCLM3 cells assessed as reduction in intracellular ATP level at 10 nM by CellTiter-Lumni plus cell viability assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824735Cytotoxicity against PC knockout human HepG2 cells assessed as reduction in cell viability at 20 to 100 nM measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824696Effect on cell cycle arrest in human HepG2 cells assessed as decrease in accumulation of cells at G0/G1 phase incubated for 24 hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID420703Inhibition of bovine brain tubulin by spectrophotometry2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID1824743Anti-invasive activity in human SK-HEP1 cells overexpressing PC assessed as suppression of cell invasion at 0.05 nM measured after 48 hrs by transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (9.26)18.2507
2000's5 (9.26)29.6817
2010's12 (22.22)24.3611
2020's32 (59.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (96.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
thiocholchicine[no description available]medium20
fosbretabulin[no description available]medium60stilbenoid
podophyllotoxin[no description available]medium30furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
3,3',4,5'-tetramethoxy-trans-stilbene[no description available]medium10
dmu-212[no description available]medium20
1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene[no description available]medium20
colchicine[no description available]medium20alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
combretastatin a-4 disodium phosphate[no description available]medium10
(4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone[no description available]medium10
resveratrol[no description available]medium10resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
3,3',4,5'-tetrahydroxystilbene[no description available]medium10catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
trans-2,3',4,5'-tetrahydroxystilbene[no description available]medium10stilbenoid
pterostilbene[no description available]medium10diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
gentamicin sulfate[no description available]medium10
oxaloacetic acid[no description available]medium10C4-dicarboxylic acid;
oxo dicarboxylic acid		geroprotector;
metabolite
aspartic acid[no description available]medium10aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
octyl gallate[no description available]medium10gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
dendrophenol[no description available]medium20
Hircinol[no description available]medium10phenanthrenes
rhapontin[no description available]medium10rhaponticinangiogenesis inhibitor;
anti-allergic agent;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
hypoglycemic agent;
neuroprotective agent;
plant metabolite
gigantol[no description available]medium10
cyclic diadenosine phosphate[no description available]medium10adenyl ribonucleotide;
cyclic purine dinucleotide		Mycoplasma genitalium metabolite
phenol[no description available]medium390phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
bibw 2992[no description available]medium10aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
ruthenium[no description available]medium10iron group element atom;
platinum group metal atom
1,7-phenanthroline[no description available]medium10phenanthroline
fluorine[no description available]medium10diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
warfarin[no description available]medium10benzenes;
hydroxycoumarin;
methyl ketone
scoparone[no description available]medium10aromatic ether;
coumarins		anti-allergic agent;
anti-inflammatory agent;
antihypertensive agent;
antilipemic drug;
immunosuppressive agent;
plant metabolite
naringenin[no description available]medium10(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
combretastatin[no description available]medium10
cytochrome c-t[no description available]medium10
2,3,4,6-tetrachlorophenol[no description available]medium10tetrachlorophenolxenobiotic metabolite
complestatin[no description available]medium10cyclic ether;
heterodetic cyclic peptide;
indoles;
organic heterobicyclic compound;
organochlorine compound;
peptide antibiotic;
polyphenol		anti-HIV-1 agent;
antimicrobial agent;
HIV-1 integrase inhibitor;
metabolite
benzene[no description available]medium10aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
naphthalene[no description available]medium10naphthalenes;
ortho-fused bicyclic arene		apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component
mtt formazan[no description available]medium10
pyrazolanthrone[no description available]medium10anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
lactic acid[no description available]medium102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
formazans[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
Angiogenesis, Pathologic0low30
Angiogenesis, Pathological0low30
Arthritis, Gouty0low10
Benign Neoplasms0low10
Bladder Cancer0low10
Bladder Neoplasms0low10
Bladder Tumors0low10
Bone Cancer0low10
Bone Neoplasms0low10
Breast Cancer0low40
Breast Carcinoma0low40
Breast Neoplasms0low40
Breast Tumors0low40
Cancer0low10
Cancer of Bladder0low10
Cancer of Bone0low10
Cancer of Breast0low40
Cancer of Colon0low30
Cancer of Esophagus0low10
Cancer of Liver0low70
Cancer of Lung0low30
Cancer of Mouth0low10
Cancer of Nasopharynx0low20
Cancer of Skin0low20
Cancer of Stomach0low10
Cancer of the Bladder0low10
Cancer of the Bone0low10
Cancer of the Breast0low40
Cancer of the Colon0low30
Cancer of the Esophagus0low10
Cancer of the Liver0low70
Cancer of the Lung0low30
Cancer of the Mouth0low10
Cancer of the Nasopharynx0low20
Cancer of the Skin0low20
Cancer of the Stomach0low10
Cancer, Hepatocellular0low70
Carcinogenesis0low10
Carcinoma, Epidermoid0low10
Carcinoma, Hepatocellular0low60
Carcinoma, Lewis Lung0low10
Carcinoma, Oat Cell0low10
Carcinoma, Planocellular0low10
Carcinoma, Small Cell0low10
Carcinoma, Squamous0low10
Carcinoma, Squamous Cell0low10
Central Nervous System Neoplasm0low10
Central Nervous System Neoplasms0low10
Central Nervous System Neoplasms, Primary0low10
Central Nervous System Tumor0low10
Central Nervous System Tumors0low10
CNS Neoplasm0low10
CNS Neoplasms0low10
Colitis Gravis0low10
Colitis, Ulcerative0low10
Colon Cancer0low30
Colon Neoplasms0low30
Colonic Cancer0low30
Colonic Neoplasms0low30
Colorectal Cancer0low30
Colorectal Carcinoma0low30
Colorectal Neoplasms0low30
Colorectal Tumors0low30
Condition, Preneoplastic0low10
Conditions, Preneoplastic0low10
Diabetes Mellitus, Adult-Onset0low10
Diabetes Mellitus, Ketosis-Resistant0low10
Diabetes Mellitus, Maturity-Onset0low10
Diabetes Mellitus, Non Insulin Dependent0low10
Diabetes Mellitus, Non-Insulin-Dependent0low10
Diabetes Mellitus, Noninsulin Dependent0low10
Diabetes Mellitus, Noninsulin-Dependent0low10
Diabetes Mellitus, Slow-Onset0low10
Diabetes Mellitus, Stable0low10
Diabetes Mellitus, Type 20low10
Diabetes Mellitus, Type II0low10
Disease Models, Animal0low20
ER-Negative PR-Negative HER2-Negative Breast Cancer0low10
ER-Negative PR-Negative HER2-Negative Breast Neoplasms0low10
Esophageal Cancer0low10
Esophageal Neoplasms0low10
Esophageal Squamous Cell Carcinoma0low10
Esophagus Cancer0low10
Esophagus Neoplasm0low10
Experimental Neoplasms0low10
Fatty Liver, Nonalcoholic0low10
Gastric Cancer0low10
Gastric Cancer, Familial Diffuse0low10
Gastric Neoplasms0low10
Gouty Arthritis0low10
Hepatic Cancer0low70
Hepatic Neoplasms0low70
Hepatocellular Cancer0low70
Hepatocellular Carcinoma0low60
Hepatoma0low60
Human Mammary Carcinoma0low40
Idiopathic Proctocolitis0low10
Inflammation0low10
Inflammatory Bowel Disease, Ulcerative Colitis Type0low10
Innate Inflammatory Response0low10
Invasiveness, Neoplasm0low30
Leucocythaemia0low10
Leucocythemia0low10
Leukemia0low10
Leukemia L 12100low10
Leukemia L12100low10
Leukemia P3880low10
Liver Cancer0low70
Liver Cancer, Adult0low60
Liver Cell Carcinoma0low60
Liver Cell Carcinoma, Adult0low60
Liver Neoplasms0low70
Lung Cancer0low30
Lung Neoplasms0low30
Malignancy0low10
Malignant Melanoma0low30
Malignant Neoplasm of Breast0low40
Malignant Neoplasms0low10
Malignant Tumor of Breast0low40
Malignant Tumor of Urinary Bladder0low10
Mammary Cancer0low40
Mammary Carcinoma, Human0low40
Mammary Neoplasm, Human0low40
Mammary Neoplasms, Human0low40
Maturity-Onset Diabetes0low10
Maturity-Onset Diabetes Mellitus0low10
Melanoma0low30
Metastase0low10
Metastases, Neoplasm0low10
Metastasis0low10
Metastasis, Neoplasm0low10
MODY0low10
Mouth Cancer0low10
Mouth Neoplasms0low10
NAFLD0low10
Nasopharyngeal Cancer0low20
Nasopharyngeal Carcinoma0low10
Nasopharyngeal Neoplasms0low20
Nasopharynx Cancer0low20
Nasopharynx Neoplasms0low20
Neoplasia0low10
Neoplasm0low10
Neoplasm Invasion0low30
Neoplasm Invasiveness0low30
Neoplasm Metastases0low10
Neoplasm Metastasis0low10
Neoplasms0low10
Neoplasms, Benign0low10
Neoplasms, Bladder0low10
Neoplasms, Bone0low10
Neoplasms, Breast0low40
Neoplasms, Central Nervous System0low10
Neoplasms, Colonic0low30
Neoplasms, Colorectal0low30
Neoplasms, Esophageal0low10
Neoplasms, Experimental0low10
Neoplasms, Gastric0low10
Neoplasms, Hepatic0low70
Neoplasms, Liver0low70
Neoplasms, Lung0low30
Neoplasms, Mouth0low10
Neoplasms, Nasopharyngeal0low20
Neoplasms, Oral0low10
Neoplasms, Pulmonary0low30
Neoplasms, Skin0low20
Neoplasms, Stomach0low10
Neovascularization, Optic Disc0low10
Neovascularization, Pathologic0low30
Neovascularization, Pathological0low30
Neovascularization, Retinal0low10
Neuroblastoma0low10
NIDDM0low10
Non-alcoholic Fatty Liver Disease0low10
Nonalcoholic Fatty Liver Disease0low10
Nonalcoholic Steatohepatitis0low10
Noninsulin-Dependent Diabetes Mellitus0low10
Oat Cell Carcinoma0low10
Oncogenesis0low10
Optic Disc Neovascularization0low10
Optic Disk Neovascularization0low10
Oral Cancer0low10
Oral Neoplasms0low10
Osteogenic Sarcoma0low10
Osteosarcoma0low10
Osteosarcoma Tumor0low10
P388D(1) Leukemia0low10
Palmoplantaris Pustulosis0low10
Pathologic Angiogenesis0low30
Pathologic Neovascularization0low30
Peritonitis0low10
Precancerous Conditions0low10
Preneoplastic Condition0low10
Preneoplastic Conditions0low10
Primary Central Nervous System Neoplasm0low10
Primary Central Nervous System Neoplasms0low10
Primary Peritonitis0low10
Psoriasis0low10
Pulmonary Cancer0low30
Pulmonary Neoplasms0low30
Pustular Psoriasis of Palms and Soles0low10
Pustulosis of Palms and Soles0low10
Pustulosis Palmaris et Plantaris0low10
Retinal Neovascularization0low10
Sarcoma, Osteogenic0low10
Sea Fan Neovascularization0low10
Secondary Peritonitis0low10
Sensitivity and Specificity0low10
Skin Cancer0low20
Skin Neoplasms0low20
Small Cell Carcinoma0low10
Squamous Cell Carcinoma0low10
Stomach Cancer0low10
Stomach Neoplasms0low10
Triple Negative Breast Cancer0low10
Triple Negative Breast Neoplasms0low10
Triple-Negative Breast Cancer0low10
Triple-Negative Breast Neoplasm0low10
Tumorigenesis0low10
Tumors0low10
Tumors, Breast0low40
Tumors, Central Nervous System0low10
Type 2 Diabetes0low10
Type 2 Diabetes Mellitus0low10
Ulcerative Colitis0low10
Urinary Bladder Cancer0low10
Urinary Bladder Neoplasms0low10

Research Highlights

Safety/Toxicity (2)

ArticleYear
Synergistic cytotoxicity of erianin, a bisbenzyl in the dietetic Chinese herb Dendrobium against breast cancer cells.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 149		2021
Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
Journal of medicinal chemistry, Apr-15, Volume: 37, Issue: 8		1994
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (1)

ArticleYear
Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of erianin for intravenous injection in dogs.
Arzneimittel-Forschung, Volume: 59, Issue: 3		2009
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (2)

ArticleYear
Recent advances of antitumor leading compound Erianin: Mechanisms of action and structural modification.
European journal of medicinal chemistry, Dec-05, Volume: 261		2023
Erianin-Loaded Photo-Responsive Dendrimer Mesoporous Silica Nanoparticles: Exploration of a Psoriasis Treatment Method.
Molecules (Basel, Switzerland), Sep-26, Volume: 27, Issue: 19		2022
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (1)

ArticleYear
Ecust004 Suppresses Breast Cancer Cell Growth, Invasion, and Migration via EMT Regulation.
Drug design, development and therapy, Volume: 15		2021
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]